Efficacy, Safety, and Biomarkers of Neoadjuvant Bevacizumab, Radiation Therapy, and Fluorouracil in Rectal Cancer: A Multidisciplinary Phase II StudyChristopher G. Willett, Yves Boucher, Marek Ancukiewicz et al.|Journal of Clinical Oncology|2009Cited by 507
Surrogate Markers for Antiangiogenic Therapy and Dose-Limiting Toxicities for Bevacizumab With Radiation and Chemotherapy: Continued Experience of a Phase I Trial in Rectal Cancer PatientsChristopher G. Willett, Gregory Y. Lauwers, Yves Boucher et al.|Journal of Clinical Oncology|2005Cited by 419